Miralles Gines Diego 4

What Happened

• Diego Miralles Gines, President & Head of R&D of Artiva Biotherapeutics (ARTV), was granted equity awards on 2026-05-18. The Form 4 reports an award of 77,500 restricted stock units (RSUs) and a stock option award covering 232,500 shares. Both grants show an acquisition price of $0.00 (i.e., they were awarded, not purchased).

Key Details

• Transaction date: 2026-05-18; Form 4 filed 2026-05-19 (timely).
• Award types and amounts: 77,500 RSUs (footnote F1) and 232,500 stock option shares (footnote F2); total of 310,000 shares underlying awards.
• Price: $0.00 per share (award/grant).
• Vesting for the option (F3): 25% of option shares vest and become exercisable on May 15, 2027; remaining option shares vest at a rate of 1/36th per month thereafter.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Filing timeliness: filing appears timely (no late filing flag).

Context

• RSUs are equity awards that convert into shares upon vesting; the option award is a derivative security that must be exercised to obtain shares. Neither award indicates an immediate sale or cashless exercise.
• These grants were made under the issuer’s 2025 Inducement Plan (per footnotes), commonly used to compensate or retain executives; this is an admission of equity compensation rather than an open-market purchase or sale.
• As always, awards reflect company compensation decisions and should not be interpreted on their own as a buy/sell signal.